ArticleAsia-Pacific journal of clinical oncology2026
Real-World Survival Outcomes in EGFR-Mutant Advanced NSCLC Treated With EGFR TKIs: Insights From a Single-Center Clinical Data Warehouse Analysis in South Korea.
Article in Asia-Pacific journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Survival Outcomes in EGFR-Mutant Advanced NSCLC Treated With EGFR TKIs: Insights From a Single-Center Clinical Data Warehouse Analysis in South Korea.Asia-Pacific journal of clinical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to evaluate real-world survival outcomes of patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC) by the generation of EGFR tyrosine kinase inhibitor (TKI) as a first-line treatment.
methodsA total of 893 patients with advanced EGFR-mutant NSCLC between January 2010 and June 2020 were identified through the clinical data warehouse-fully aligned with the electronic medical records-at Seoul National University Hospital in South Korea. Kaplan-Meire and multivariate Cox proportional hazard regression analyses were conducted to explore the overall survival (OS) between patients treated with first-/second-generation as their first-line treatment (1G/2G first) and third generation first-line EGFR TKIs (3G first).
resultsOf the 893 patients, 831 patients (93.1%) were in the 1G/2G first group, and 62 patients (6.9%) were in 3G first group. In 1G/2G first group, 324 (39.0%) switched to the next therapy with 3G EGFR TKI. The median OS for 1G/2G first group was 35.6 months (95% confidence interval [CI]: 31.1-39.1) and those for 3G first group was 47.6 months (95% CI: 41.4-not estimable [NE]). Multivariate Cox regression analysis revealed that first-line treatment with 3G EGFR TKIs conferred a significant survival benefit compared with 1G/2G TKIs (HR: 0.64; 95% CI: 0.45-0.92; p = 0.015). In addition, subgroup analysis showed that patients with brain metastases had significantly better survival with first-line 3G EGFR TKIs than with 1G/2G agents (HR: 0.54; 95% CI, 0.31-0.94; p = 0.031).
conclusionBased on real-world data, first-line treatment with 3G EGFR TKIs demonstrated a significant survival benefit compared with 1G/2G EGFR TKIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.